Bayer's Sunharbo Green Light Shifts the Debate From Pipeline Promise to Profit Proof
Published on 11/11/2026 at 21:31 | Editorial boerse-global.de
Bayer investors have spent the past week weighing two very different kinds of news: a regulatory milestone for its pharmaceutical arm and a courtroom reprieve for its embattled crop-science division. The market's reaction has been split down the middle, with two major research houses landing on opposite sides of the same stock.
Jefferies reiterated its "Hold" rating on Bayer with a price target of EUR 48.50, a level the shares have already left behind — the stock was trading at EUR 56.70. Deutsche Bank Research, by contrast, raised its target from EUR 60 to EUR 65 and stuck with its "Buy" recommendation, placing its mark comfortably above the current quote.
Two approvals, one strategy
The more consequential development came on Monday, when the FDA cleared SUNHARBO, whose active ingredient is asundexian, for reducing stroke risk in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The approval covers use in combination with an antiplatelet therapy. Bayer expects shipments to begin between mid- and late November.
The company bills the drug as the world's first approved factor XIa inhibitor, a designation underpinned by the Phase III OCEANIC-STROKE trial. A second regulatory win arrived just days earlier in China, where Sevabertinib was authorized for first-line treatment of adults with advanced HER2-mutated non-small cell lung cancer.
Should investors sell immediately? Or is it worth buying Bayer?
For shareholders, the appeal is straightforward: a development programme has cleared its final regulatory hurdle. The harder test comes next — turning those approvals into revenue and earnings. That transition from laboratory to ledger is where a green light earns its place in a valuation.
The numbers behind the optimism
Harder evidence than approvals alone came roughly a week ago with the release of third-quarter figures. Bayer posted group revenue of EUR 10.053 billion, up 4.1%, while EBITDA before special items reached EUR 1.615 billion, a gain of 6.9%. Pharmaceuticals drove the growth, and that combination — a division already delivering profit while simultaneously producing newly approved medicines — is the strongest argument in the bull case.
Alongside the quarterly results, Bayer lifted its full-year 2026 outlook for EBITDA before special items to a range of EUR 9.8 billion to EUR 10.3 billion, up from the EUR 9.6 billion to EUR 10.1 billion previously guided. Management also set a concrete marker for the Pharmaceuticals margin at 25% to 27%, giving profitability a measurable benchmark against which the approval story can be judged.
Where the analysts part ways
The reasoning behind the diverging recommendations is instructive. Deutsche Bank pointed to the better-than-expected third quarter and raised estimates for the closing quarter, both carried by Pharmaceuticals. Jefferies analyst Michael Leuchten called the asundexian approval broadly expected, though he acknowledged the risk to Bayer's pharma pipeline had fallen considerably.
Momentum has raised the bar for the next test. The shares have climbed 53% since the start of the year, meaning expectations are now priced in and must be met with delivery.
Bayer at a turning point? This analysis reveals what investors need to know now.
A courtroom win, with caveats
On the legal front, a Missouri jury voted unanimously in Monsanto's favour on 30 October in a Roundup case brought by three plaintiffs, according to media reports. The verdict settles only that specific trial and has no bearing on Bayer's separately pending settlement proposal.
The next hard checkpoint arrives on 24 February 2027, when Bayer publishes its 2026 annual results. How the strength of Pharmaceuticals filters through to the group's bottom line will determine whether the recent rally has room to run — or whether the approval-driven enthusiasm has already run its course.
Ad
Bayer Stock: New Analysis - 11 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
